Patrick J. Roberts, Ph.D.
Affiliations: | 2007 | Pharmaceutical Sciences | University of North Carolina, Chapel Hill, Chapel Hill, NC |
Area:
Pharmacology, Oncology, PathologyGoogle:
"Patrick Roberts"Parents
Sign in to add mentor| Channing J. Der | grad student | 2007 | UNC Chapel Hill | |
| (Targeting Ras and Rho family GTPases for the treatment of cancer through inhibition of CAAX-signaled modifications and the ERK MAPK pathway.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dietrich C, Trub A, Ahn A, et al. (2023) INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discovery |
| Roberts PJ, Kumarasamy V, Witkiewicz AK, et al. (2020) Chemotherapy and CDK4/6 inhibitors: Unexpected bedfellows. Molecular Cancer Therapeutics |
| Weiss JM, Csoszi T, Maglakelidze M, et al. (2019) Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology |
| O'Shaughnessy J, Wright G, Thummala A, et al. (2019) Abstract PD1-01: Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results Cancer Research. 79 |
| Goodwin CM, Javaid S, Waters AM, et al. (2019) Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer Cancer Research. 79 |
| Dai B, Freed DM, Sorrentino JA, et al. (2019) Abstract 4732: CDK4/6 inhibition with lerociclib (G1T38) enhances response to PI3K or ERK inhibitors in high-throughput, ex vivo pancreatic PDX screens Cancer Research. 79: 4732-4732 |
| Freed DM, Hall CR, Strum JC, et al. (2019) Abstract 4415: CDK4/6 inhibition with lerociclib (G1T38) delays acquired resistance to targeted therapies in preclinical models of non-small cell lung cancer Cancer Research. 79: 4415-4415 |
| Sorrentino JA, Lai A, Weiss JM, et al. (2018) Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii598 |
| Dragnev KH, Owonikoko TK, Csoszi T, et al. (2018) Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii597 |
| Lai AY, Sorrentino JA, Strum JC, et al. (2018) Abstract 1752: Transient exposure of trilaciclib, a CDK4/6 inhibitor, modulates gene expression in tumor immune infiltrates to promote a pro-inflammatory tumor microenvironment Cancer Research. 78: 1752-1752 |